Related Experiment Videos
[Fenoldopam: potential clinical applications in heart surgery]
1Department of Anaesthesia and Intensive Care Medicine, University College, Cork, Irlanda.
Revista Espanola De Anestesiologia Y Reanimacion
|January 17, 2002
Summary
Fenoldopam mesylate, a selective dopamine-1 receptor agonist, enhances renal blood flow and reduces vascular resistance. This medication may benefit conditions requiring improved kidney oxygen supply and reduced demand.
Area of Science:
- Pharmacology
- Nephrology
- Cardiovascular Science
Context:
- Fenoldopam mesylate is a unique benzazepine derivative and the first selective dopamine-1 (DA1) receptor agonist approved for medical use.
- It exhibits specific actions on smooth muscle relaxation, vasodilation, and renal sodium handling.
- Unlike other agents, it lacks dopamine-2, alpha, or beta-adrenergic activity.
Purpose:
- To evaluate the effects of fenoldopam mesylate on renal hemodynamics.
- To assess its potential utility in managing conditions with altered renal oxygen balance.
Summary:
- Fenoldopam mesylate selectively activates dopamine-1 receptors, leading to vasodilation and increased renal blood flow.
- It is significantly more potent than dopamine in dilating renal vessels.
- Intravenous administration resulted in increased renal blood flow and decreased vascular resistance in both healthy individuals and hypertensive patients.
Impact:
- Fenoldopam mesylate demonstrates potential for improving renal perfusion.
- Its selective action may offer therapeutic advantages in clinical scenarios demanding enhanced renal oxygen supply.
- The findings support its use in managing renal blood flow and vascular resistance, particularly in hypertensive patients.